European Society For Medical Oncology

Evidence for efficacy is based on the results from the PERSEUS study

Findings from the IMADGIST study

The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open

Findings from extended follow-up of the DeLLphi-300 study

Evidence for efficacy is based on the results from the MARIPOSA study

Evidence for efficacy is based on the results from the PERSEUS study

Findings from the IMADGIST study

Findings from extended follow-up of the DeLLphi-300 study

Evidence for efficacy is based on the results from the MARIPOSA study

Findings from the ProBio study

Evidence for efficacy is based on the results from the RUBY study

Findings from the largest meningioma cohort including a prospective set from the RTOG-0539 study

The combination is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy

Findings from the HERB study

The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open

According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers.

The ESMO Congress 2024 will take place from September 13-17 in Barcelona, bringing together participants from all over the world

Treatment of gastrointestinal (GI) cancers is catching up with other areas of oncology and offering patients better prospects for survival and quality of life, but a significant uptick in early-onset cases is raising new questions about effective prevention, diagnosis and treatment

Cross-border tumour boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynaecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress 2024

The European Society for Medical Oncology is pleased to announce the ESMO Gastrointestinal Cancers Congress 2024, the scientific congress entirely dedicated to the presentation of advances and discussions around the prevention, diagnosis and management of malignancies of the gastrointestinal tract

The ESMO Gynaecological Cancers Congress 2024 will be held in Florence, Italy, between 20-22 June, hosting international experts who will present and discuss the latest developments in the biology, diagnosis and therapy of gynaecological tumours

Ahead of World No Tobacco Day 2024, European scientific, healthcare professional and other civil society organisations call for an EU Endgame on Tobacco

First global study in young women with high-risk genes and a pregnancy after breast cancer shows Assisted Reproductive Techniques (ART) are safe, with no increase in breast cancer recurrence

ESMO is pleased to announce the 2024 ESMO Fellowship awardees

The ESMO Precision Medicine Working Group (PMWG) together with a multidisciplinary team of international experts, have developed the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S)

The recipients of the 2024 ESMO Society Awards have been announced today by ESMO

Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research

The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics

ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.

Tom Powles, Editor in Chief of ESMO’s flagship journal Annals of Oncology; Solange Peters, ESMO Past President; and Fabrice André, President Elect of the Society have been recognised as leading and influential researchers for their remarkable achievements in cancer care

Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation

The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center